Ziltivekimab reduces inflammation, not MACE risk in patients with atherosclerosis, CKD

Ziltivekimab, a novel interleukin-6 inhibitor, reduced inflammatory markers in patients with atherosclerosis and chronic kidney disease but did not lower risk for major adverse CV events, according to the topline results of the ZEUS trial.For the double-blind, placebo-controlled, phase 3 ZEUS trial, researchers enrolled more than 6,300 patients with atherosclerotic CVD, chronic kidney disease